NCT05106387 An Observational Extension Study for Adult Patients Treated in Study R5459-RT-1944 Who Receive a Kidney Transplant
| NCT ID | NCT05106387 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Regeneron Pharmaceuticals |
| Condition | Chronic Kidney Disease (CKD) |
| Study Type | OBSERVATIONAL |
| Enrollment | 20 participants |
| Start Date | 2023-10-19 |
| Primary Completion | 2027-06-14 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 20 participants in total. It began in 2023-10-19 with a primary completion date of 2027-06-14.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The main purpose of this study is to continue to see how vonsetamig works in the body and to monitor the outcomes after kidney transplant for participants previously treated in the R5459-RT-1944 study (NCT05092347). No study drug will be given during this study.
Eligibility Criteria
Inclusion Criteria: 1. Received at least 1 dose of treatment with vonsetamig in study R5459-RT-1944 \[NCT05092347\]. 2. Received after acceptable crossmatching, a kidney transplant while enrolled in study R5459-RT-1944 3. Willing and able to comply with clinic visits and study-related procedures 4. Provide informed consent signed by study patient or legally acceptable representative Exclusion Criteria: 1.There are no exclusion criteria for this study. Note: Other protocol defined Inclusion/Exclusion criteria may apply
Contact & Investigator
Clinical Trial Management
STUDY DIRECTOR
Regeneron Pharmaceuticals
Frequently Asked Questions
Who can join the NCT05106387 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, up to 70 Years, studying Chronic Kidney Disease (CKD). Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT05106387 currently recruiting?
Yes, NCT05106387 is actively recruiting participants. Contact the research team at clinicaltrials@regeneron.com for enrollment information.
Where is the NCT05106387 trial being conducted?
This trial is being conducted at Los Angeles, United States, Orange, United States, San Francisco, United States, New Haven, United States and 5 additional locations.
Who is sponsoring the NCT05106387 clinical trial?
NCT05106387 is sponsored by Regeneron Pharmaceuticals. The principal investigator is Clinical Trial Management at Regeneron Pharmaceuticals. The trial plans to enroll 20 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.